Search
VolitionRX Ltd
VNRXAdd to Watchlist
2.000USD
-0.150-6.82%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
16.66MMarket Cap
LossP/E TTM
More Details of VolitionRX Ltd Company
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRX Ltd Info
Ticker SymbolVNRX
Company nameVolitionRX Ltd
IPO dateFeb 06, 2015
CEOButera (Salvatore Thomas)
Number of employees85
Security typeOrdinary Share
Fiscal year-endFeb 06
Address1489 West Warm Springs Road
CityHENDERSON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code89014
Phone17024251561
Websitehttps://volition.com/
Ticker SymbolVNRX
IPO dateFeb 06, 2015
CEOButera (Salvatore Thomas)
Company Executives of VolitionRX Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
196.86K
+5.92%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
133.66K
+10.94%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
18.94K
+14.10%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
18.19K
-3.54%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
16.56K
-2.28%
Ms. Kim Nguyen
Ms. Kim Nguyen
Independent Director
Independent Director
16.19K
+61.15%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
13.70K
-2.65%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
196.86K
+5.92%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
133.66K
+10.94%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
18.94K
+14.10%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cotterford Co., Ltd.
7.42%
Lagoda Investment Management, L.P.
7.09%
The Lind Partners, LLC
2.76%
Innes (Guy Archibald)
2.43%
Reynolds (Cameron John)
1.65%
Other
78.65%
Shareholders
Shareholders
Proportion
Cotterford Co., Ltd.
7.42%
Lagoda Investment Management, L.P.
7.09%
The Lind Partners, LLC
2.76%
Innes (Guy Archibald)
2.43%
Reynolds (Cameron John)
1.65%
Other
78.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor
11.58%
Corporation
8.04%
Individual Investor
7.07%
Investment Advisor/Hedge Fund
1.07%
Research Firm
0.17%
Hedge Fund
0.14%
Bank and Trust
0.03%
Other
71.89%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
66
1.13M
13.93%
-209.80K
2025Q4
58
26.12M
21.27%
+1.98M
2025Q3
57
23.92M
20.70%
+1.72M
2025Q2
78
41.39M
40.30%
+860.69K
2025Q1
83
44.42M
46.85%
+2.70M
2024Q4
82
41.53M
44.82%
+1.50M
2024Q3
82
38.59M
41.90%
+9.42M
2024Q2
82
28.77M
32.86%
+105.49K
2024Q1
84
28.22M
34.52%
+1.47M
2023Q4
87
26.17M
37.10%
+183.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cotterford Co., Ltd.
12.01M
8.73%
--
--
Feb 09, 2026
Lagoda Investment Management, L.P.
11.46M
8.34%
-1.02M
-8.20%
Dec 31, 2025
The Lind Partners, LLC
4.46M
3.25%
+4.46M
--
Feb 09, 2026
Innes (Guy Archibald)
3.94M
2.86%
+233.25K
+6.30%
Feb 26, 2026
Reynolds (Cameron John)
2.67M
1.94%
+292.42K
+12.28%
Feb 26, 2026
Concord International Inc.
1.01M
0.73%
--
--
Feb 09, 2026
Geode Capital Management, L.L.C.
963.99K
0.7%
+85.82K
+9.77%
Dec 31, 2025
Hughes (Terig)
639.35K
0.46%
+202.00K
+46.19%
Feb 26, 2026
Micallef (Jacob Vincent)
623.85K
0.45%
-5.31K
-0.84%
Mar 17, 2026
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 17, 2026
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Apr 17, 2026
Merger
20→1
